Epithelial Cell Cytology in Breast Cancer Risk Assessment
This policy governs BCBSOK reimbursement for cytologic analysis of epithelial cells from nipple aspiration/ductal lavage used to assess breast cancer risk, and applies to providers submitting claims to Blue Cross Blue Shield - Oklahoma.
Document updated with literature review; reimbursement information unchanged.
New policy created on 11/1/2022.
Coverage Criteria — Nipple Aspiration Cytology
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.